New drug combo targets Hard-to-Treat cancers with genetic weakness
NCT ID NCT07277413
First seen Dec 16, 2025 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This early-stage trial is testing a new drug called IDE892, alone or combined with another drug (IDE397), in people with advanced solid tumors that lack a gene called MTAP. The study aims to find safe doses and see if the drugs can shrink tumors. About 260 adults with cancers like lung, stomach, bladder, or pancreatic cancer are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Dallas
RECRUITINGIrving, Texas, 75039, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Houston
RECRUITINGHouston, Texas, 77054, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nebraska Cancer Specialists
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Dallas Fort Worth
RECRUITINGFort Worth, Texas, 76104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Mountain Region, LLC
RECRUITINGWest Valley City, Utah, 84119, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sarah Cannon Research Institute at Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-••••
-
Swedish Cancer Institute
RECRUITINGSeattle, Washington, 98104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IDE892 (a PRMT5 inhibitor) and IDE397 (a MAT2A inhibitor)
What this could lead to
If successful, this could lead to a new treatment option for several hard-to-treat cancers that have a specific genetic deletion (MTAP).
What could go wrong
This is a very early (Phase 1) trial with a small number of participants, so safety and effectiveness are not yet known. The drug may not shrink tumors or could cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.